Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T11:46:02.898Z.
Consensus retrieved: 2026-10-06T09:34:18.309Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T11:46:02.898Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb7cd459c06c6daeeda89392674d56a21e8de13f6e28d09f8b66476fbbf92c22
Forward PE Ratio (N/A) = Dated Quote Price ($57.54) / Consensus Forward EPS ($5.00)
FORWARD PE RATIO
N/A
BioMarin Pharmaceutical Inc.
Market Cap
$11.12B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BioMarin Pharmaceutical Inc. (BMRN) | $11.12B | N/A |
| The Cooper Companies, Inc. (COO)vs › | $11.07B | 12.50 |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 35.48 |
| DaVita Inc. (DVA)vs › | $11.47B | 12.10 |
| Universal Health Services, Inc. (UHS)vs › | $10.66B | 7.80 |
| Globus Medical, Inc. (GMED)vs › | $10.33B | 15.31 |
| Encompass Health Corporation (EHC)vs › | $12.00B | 19.79 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.22B | 38.96 |
| Molina Healthcare, Inc. (MOH)vs › | $10.13B | N/A |
| The Ensign Group, Inc. (ENSG)vs › | $10.08B | 22.18 |
Trailing P/E
147.5
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $5.00 implies +1182.1% EPS growth vs the reported trailing $0.39.
At the dated quote price of $57.54, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $5.00 | $4.86 – $5.08 | 16 | 11.5x |
| 2027-12-31 | $6.66 | $5.07 – $7.72 | 16 | 8.6x |
| 2028-12-31 | $7.85 | $3.01 – $11.77 | 15 | 7.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
